Efficacy of Orally Administered Superfine Dispersed Lentinan (β-1,3-Glucan) for the Treatment of Advanced Colorectal Cancer

Department of Surgery II, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
Anticancer research (Impact Factor: 1.83). 07/2009; 29(7):2611-7.
Source: PubMed


Lentinan (LNT) is an immune adjuvant medicine for advanced gastric cancer in Japan. Recently, an oral formulation of superfine dispersed lentinan (SDL) has become clinically available. To investigate the safety and effectiveness of SDL, a multi center clinical study in patients with advanced colorectal cancer was conducted.
Adverse events were assessed and the patients' quality of life (QOL) and the binding ability of peripheral blood monocytes (PBM) to LNT were also evaluated.
Four grade 2 adverse events associated with SDL treatment were observed among the 80 patients. Adverse events associated with chemotherapy were observed in 9 out of the 64 chemotherapy-treated patients. Among the 48 patients assessed for QOL, the patients with low QOL scores before SDL treatment (n=23) reported a significant improvement in their QOL scores after 12 weeks of SDL administration. The rates of LNT-binding PBM in the QOL-improved group were significantly higher than those in the QOL-not-improved group (p<0.05).
SDL was safe and effective for suppressing the adverse effects of chemotherapy as well as improving QOL. The binding ability of PBM to LNT appears to be a promising predictor of QOL improvement after SDL administration.

Download full-text


Available from: Yasuyo Suga, Aug 25, 2015
1 Follower
6 Reads
  • Source
    • "2009) and colorectal cancer (Hazama et al. 2009). Nakano et al. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This randomized, placebo-controlled, double-blind study compared the effects of daily supplementation for 4 week with 250 mg Wellmune WGP® β-1,3/1,6-Glucan (WGP) with placebo 250 mg/day (rice flour) on physical and psychological health attributes of self-described "moderate" ragweed allergy sufferers. Study participants (mean age = 36 ± 9 year; range 18-53 year) were recruited before the beginning of ragweed season (September) in Northeastern Ohio. Serum IgE concentration, allergy symptoms [via self-report, Visual Analog Scale (VAS), and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)], psychological well-being [Profile of Mood States (POMS)], and physical function (RAND SF-36 Medical Outcomes Study) were measured immediately prior to and after supplementation with WGP (n = 24) or placebo (n = 24) for 4 weeks. Data were analyzed using repeated measures analyses of variance (ANOVA). Compared with placebo, WGP reduced total allergy symptoms (28%), symptom severity (52%), and symptom rating on the VAS (37%) (P < 0.05), but had no effect on serum IgE levels. As measured by the POMS, WGP increased participants' rating of vigor (10%), but reduced tension (34%), depression (45%), anger (41%), fatigue (38%), and confusion (34%) (P < 0.05). Study participants given WGP reported increased physical health (11%), energy (19%), and emotional well-being (7%) compared with study participants given the placebo (RAND SF-36 Medical Outcomes Study). The WGP group also reported decreased sleep problems (53%), reduced nasal symptoms (59%), eye symptoms (57%), non-nasal symptoms (50%), activities (53%), emotions (57%), and improved quality of life (QOL) (56%), as well as improved global mood state (13%). Supplementation with WGP for 4 weeks improved allergy symptoms, overall physical health, and emotional well-being compared with placebo in self-described "moderate" ragweed allergy sufferers during ragweed allergy season.
    Food Science & Nutrition 01/2013; 1(1):90-101. DOI:10.1002/fsn3.11
  • [Show abstract] [Hide abstract]
    ABSTRACT: Glucan sulfates with different degree of substitution were prepared from partially sulphated insoluble β-1, 3-D-glucan isolated from Saccharomyces cerevisiae cell wall. Sulphation was done with sulfate acid (H2SO4) in dimethyl sulfoxide (DMSO) in presence of urea. Varying reaction times, temperature and ratio of H2SO4 and DMSO were used to obtain glucan sulfates with distinct degree of substitution, which was measured by barium chloride-gelatin method. The immunoprophylaxis effect of glucan sulfates in a mouse model of Escherichia coli induced peritonitis was studied and found to be related to the degree of substitution. The result showed that as the degree of substitution increased, the immunoprophylaxis efficacy increased.
    01/2010; DOI:10.1109/ICBBE.2010.5516040
  • [Show abstract] [Hide abstract]
    ABSTRACT: To examine the recent scientific literature on the immune modulating effects of β-glucans and subsequent benefits on infection and cancer. β-Glucans have been investigated for their ability to protect against infection and cancer and more recently for their therapeutic potential when combined with cancer therapy. Their immune modulating effects are attributed to the ability to bind to pattern recognition receptors including complement receptor 3, scavenger receptors, lactosylceramide, and dectin-1 that results in activation of different aspects of the immune response depending on the cell types and species involved although there is some controversy about the relative importance of each of these receptors. Most of the available evidence comes from preclinical data and human studies are just now beginning to appear in the literature, therefore firm conclusions on its clinical importance cannot yet be made. Perhaps the most promising evidence to date in human trials has come from recent studies on a benefit of β-glucan on quality of life and survival when given in combination with cancer treatment. We identify the need for future studies that compare purified forms of β-glucans from different sources to further the understanding of the mechanisms of action and aid in the development of clinical studies. β-Glucans appear to be effective at enhancing immune function and reducing susceptibility to infection and cancer. A better understanding of the mechanisms of β-glucan recognition and subsequent immune activation is necessary for the design of effective treatment approaches in future clinical trials.
    11/2010; 13(6):656-61. DOI:10.1097/MCO.0b013e32833f1afb
Show more